Kuala Lumpur Hospital is a Malaysian government-owned public hospital in Kuala Lumpur, the capital city of Malaysia. Founded in 1870, HKL is a not-for-profit institution and serves as the flagship hospital of the Malaysian public healthcare system. This hospital serves as a tertiary and referral hospital.

There are 2,300 beds in Hospital Kuala Lumpur.

During the past decade, Hospital Kuala Lumpur conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 23 clinical trials were completed, i.e. on average, 35.4% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 20 clinical trials were completed. i.e. 64.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Kuala Lumpur" #1 sponsor was "Janssen Research & Development, LLC" with 9 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Ministry of Health, Malaysia" with 3 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Kuala Lumpur" #1 collaborator was "Hospital Queen Elizabeth, Malaysia" with 3 trials as a collaborator, "Kuala Lumpur General Hospital" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Hospital Enche Besar Hajjah Khalsom, Kluang, Johor" with 2 trials as a collaborator and "Hospital Melaka, Melaka" with 2 trials as a collaborator. Other collaborators include 55 different institutions and companies that were collaborators in the rest 53 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Kuala Lumpur" are "COVID-19" (3 trials), "Generalized Pustular Psoriasis" (3 trials), "Neuromyelitis Optica Spectrum Disorder" (3 trials), "Anosmia" (2 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "Hospital Kuala Lumpur" in a lesser frequency.

Most popular intervention types in "Hospital Kuala Lumpur" are "Drug" (60 trials), "Other" (9 trials), "Biological" (8 trials), "Procedure" (7 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Carboplatin" (3 trials), "Spesolimab" (3 trials), "Amivantamab" (2 trials) and "Eylea (Aflibercept, BAY86-5321)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Kuala Lumpur" are 77 trials for "All" genders, 5 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Kuala Lumpur". 1 are not yet recruiting, 10 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Hospital Kuala Lumpur, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Kuala Lumpur, 3 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 46 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 9 trials that are defined as “Not Applicable".

Hospital Kuala Lumpur has several departments that took part in Clinical trials: "Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi" - 3 trials, "Wound Care Unit, Dept. of Internal Medicine, Kuala Lumpur Hospital" - 2 trials, "Hospital Tunku Azizah Kuala Lumpur" - 2 trials, "Clinical Research Centre, Hospital Kuala Lumpur" - 2 trials